Doxazosin in 'resistant' hypertension.
A study of doxazosin added to baseline therapy with a beta-adrenoceptor blocker plus a diuretic in the treatment of patients 'resistant' to the baseline therapy, showed that it was effective and generally well tolerated. The study was, however, open-label and lacked comparison with other third-line drugs.
Maclean
D
D
University Department of Clinical Pharmacology, Ninewells Hospital, Dundee, UK.
McDevitt
D G
DG
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004232:Diuretics / Q000627:therapeutic use*; D017292:Doxazosin; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004232:Diuretics; D017292:Doxazosin; D011224:Prazosin